Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial - Wikidata - wikimedia - TriplyDB

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial

http://www.wikidata.org/entity/Q30432880

about

Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention?Reperfusion therapies of acute ischemic stroke: potentials and failures Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.Reperfusion therapies for acute ischemic stroke: an update A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS).Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke Rationale for a nanomedicine approach to thrombolytic therapy.Review of stroke thrombolytics.Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials.The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.Intra-arterial therapy for acute ischemic stroke.Advances in medical revascularisation treatments in acute ischemic stroke.Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal.Quantification of errors in ordinal outcome scales using shannon entropy: effect on sample size calculations.Efficiency of enrollment in a successful phase II acute stroke clinical trial.Intravenous thrombolytics for ischemic stroke.Adjunctive and alternative approaches to current reperfusion therapy Drug treatment of acute ischemic stroke.Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now.How to make better use of thrombolytic therapy in acute ischemic stroke.Improving reperfusion therapy for acute ischaemic stroke.Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.Pharmacological revascularization of acute ischaemic stroke: focus on challenges and novel strategies.The use of desmoteplase (bat saliva) in the treatment of ischaemia.Strategies to improve recovery in acute ischemic stroke patients: Iberoamerican Stroke Group Consensus.Advances and challenges in treatment and prevention of ischemic stroke.Intravenous tenecteplase in acute ischemic stroke: an updated review.Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications.Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.Effect of waivers of consent on recruitment in acute stroke trials: A systematic review Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy.Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.Intravenous thrombolysis for acute stroke: current standards and future directions.Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy.An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.The future of endovascular treatment: Insights from the ESCAPE investigators.Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

P2860

Q24202641-77E05BCD-982C-41CF-A614-289F25AD11C9 Q26796472-9AE120C7-EB27-4EAB-8BAF-977ECA8C6F50 Q26825758-EA750AD3-6240-466A-A047-6AF98E5444A6 Q30277030-BBB5A9F5-4D9B-4DC3-BB3B-5EE340B24C97 Q30399762-E8BD66B3-7305-4D5F-8DBA-2CECE5D1E0EA Q30407045-2894503E-C23F-4A03-9C41-6B8FBD861C17 Q30430118-0CE57DC2-E166-4D6B-B9B6-4575D3F966D5 Q30452739-6F198CA3-C5BB-45FC-8891-31B04652CE0F Q30474015-1FA71522-4237-48A9-A990-95433BFFA6CF Q30712454-82756896-389D-44F7-84C9-DF35D5604F10 Q31122611-3DA422AC-AA19-4510-9F5B-45D2455F7CDC Q33645859-BAC4C214-0B6F-4949-8A8E-2E5E01926AD5 Q33653028-826F283E-2FEA-4CA5-8C44-3D5F73DDB849 Q34459133-59ED0193-DBA9-4709-9BD4-6D9FE5D876C1 Q34603396-EA43F3BD-D117-4773-B933-40594C856A09 Q34826078-901BF5ED-66A3-47F3-83B8-6B63B0855047 Q35087477-85C7406C-E4A9-46A6-9A5A-B740D2FEF37A Q35648096-93B44B90-C7CC-4AD0-A0DD-B799265576C5 Q35711810-FC780E7A-5089-45D2-B177-11A8825708A6 Q37342995-46B04168-9885-4A92-999E-A60882D552F2 Q37420266-2366AC59-99B9-4FE7-85F5-B181424EE1DC Q37889116-002B2FEF-7693-4A06-B8A0-DC4906BB0F56 Q37903959-0C3DAD73-2D15-40CD-AD43-2129743D29BF Q37903963-879DA897-6B81-4F77-BD9B-CE4863773725 Q37997491-D83D1ABD-6597-486C-A071-3527D97712FF Q38080143-1CD57491-6EE0-4658-83B5-52A34DBE3CB8 Q38117170-C2C483DE-87C9-4543-883A-F59D01C724C3 Q38127644-80B7BEB3-F469-4AD1-A286-F8BFDA807D34 Q38137688-42D2235A-0CB4-4C35-90ED-CDCA16D06D7F Q38225341-B091ED3B-645D-4582-A0BC-E5FFF845BC58 Q38589822-C819DFA6-0F21-4688-93B1-A94610F97D4D Q38786616-B29F0806-05E0-4213-94E8-E7DDFB2DFED2 Q38790291-C46CE822-AAAE-4928-A74E-64E8F9E8DD38 Q38917550-93280EEE-FA7A-4C93-9D11-81D022BACC30 Q39028528-6BBE8235-C450-4070-979A-529A275EFB5A Q39394485-144D1797-CD2F-453C-BBCD-D9AABC85DF1A Q39766399-F4E7E465-815E-4731-8314-0758FCB61887 Q40523644-AC036F66-4601-4D88-A3C7-79FEE0BB6558 Q47568897-CF152FEB-222D-4201-9D2F-654760FE43E9 Q47964852-09217781-7138-4E9B-835C-BF90C5843E0B

P2860

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial

http://www.wikidata.org/entity/Q30432880

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@ast

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@en

type

label

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@ast

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@en

prefLabel

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@ast

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@en

P1433

Q30432880-FB205F15-88A9-4676-A367-75036A65E642

P1476

Q30432880-11B8F16A-3A68-44AE-8A77-B9CFF224066B

P2093

Q30432880-15A5192B-3EC3-4908-BCCD-2DEE757219EF

Q30432880-3CF6573A-1BFE-41EC-A619-F79B95CEBC25

Q30432880-4B343B47-C97F-4369-B840-844A4F7F51DF

Q30432880-51A33845-336F-4BE2-9D08-DC6DAEA82CE3

Q30432880-6CBCF73D-552E-4C6F-9DB6-92E5F2C74224

Q30432880-84928CC3-5CB5-4282-82B7-D01AFB2A18FA

Q30432880-87071F81-8A68-4857-8EB3-4DA9C1B8D713

Q30432880-884101F7-15FC-46E7-8397-68F5BBA7BC25

Q30432880-A2E5F5F6-C0E3-43EC-AE1E-07E38E4C6772

Q30432880-B88F1EE7-31D4-4D1C-847F-F115A2E92908

P2860

Q30432880-02FF9A68-016A-485F-9BFE-2AF86537BC46

Q30432880-1CD5B289-F31F-4A9E-BF64-EE49078331DA

Q30432880-23670F46-49FE-4F71-8B0A-ED592D6DCE9E

Q30432880-2E82175B-D36B-4D57-A294-D60859B92BDE

Q30432880-313B2F83-88B7-4DF2-9A97-26B877333291

Q30432880-4BE2DDD6-7CF3-4ACB-8B85-782A67ADA4A2

Q30432880-A58EF9C6-4A92-4033-811F-1D27357AB41F

Q30432880-D9193ED6-1B2A-4140-9D9D-2648235E3D14

P304

Q30432880-66066F5B-98C9-4551-80F5-C3B132E28630

P31

Q30432880-0D05D836-7914-4956-8DBD-58C8C4A5FC0C

P356

Q30432880-5739B14F-28CE-4EB8-AB19-D299654DAA12

P407

Q30432880-A6C4B8CF-41EF-4B1F-B8A1-CBDFC523523B

P433

Q30432880-020ECBA3-43EB-4549-BC30-77FF3D9E0B72

P478

Q30432880-B11539E9-D4CA-4D1F-A787-76A7FBA51C36

P50

Q30432880-18016E56-9536-443F-B035-0792B1E99613

Q30432880-92E10503-AC30-4FC3-B1AB-4147E923064E

P577

Q30432880-CAB77D39-7BF0-426D-9E64-33E57616FD5B

P698

Q30432880-6C0E184C-5A2B-4CCA-B549-79B86A80B480

P932

Q30432880-8CBBC449-95FF-4959-A364-DE66310A95B5

P356

STROKEAHA.109.572040

P1433

P1476

Phase IIB/III trial of tenecte ...... ated randomized clinical trial

@en

P2093

Bruce Levin

http://www.w3.org/2001/XMLSchema#string

Christopher Fanale

http://www.w3.org/2001/XMLSchema#string

E Clarke Haley

http://www.w3.org/2001/XMLSchema#string

Gilberto Levy

http://www.w3.org/2001/XMLSchema#string

James C Grotta

http://www.w3.org/2001/XMLSchema#string

John L P Thompson

http://www.w3.org/2001/XMLSchema#string

Karen C Johnston

http://www.w3.org/2001/XMLSchema#string

Patrick D Lyden

http://www.w3.org/2001/XMLSchema#string

Richard Buchsbaum

http://www.w3.org/2001/XMLSchema#string

Richard Libman

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

Guidelines for the Early Management of Adults With Ischemic Stroke

Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.

A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.

Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.

Interobserver agreement for the assessment of handicap in stroke patients.

NIHSS training and certification using a new digital video disk is reliable.

Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window.

P304

707-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.109.572040

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20185783

http://www.w3.org/2001/XMLSchema#string

P932

2860601

http://www.w3.org/2001/XMLSchema#string